MorphoSys Corporate Presentation 2023 Cancer Treatment

MorphoSys outlines its oncology-focused strategy centered on tafasitamab/Monjuvi for relapsed/refractory diffuse large B-cell lymphoma, with pipeline programs including tulmimetostat and pelabresib. The company maintains strong cash runway extending into 2025 to support clinical development and commercial expansion across multiple cancer indications.